KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Goodwill & Intangibles (2022 - 2025)

Rigel Pharmaceuticals (RIGL) has 4 years of Goodwill & Intangibles data on record, last reported at $24.7 million in Q4 2025.

  • For Q4 2025, Goodwill & Intangibles fell 8.68% year-over-year to $24.7 million; the TTM value through Dec 2025 reached $24.7 million, down 8.68%, while the annual FY2025 figure was $24.7 million, 8.68% down from the prior year.
  • Goodwill & Intangibles reached $24.7 million in Q4 2025 per RIGL's latest filing, down from $25.3 million in the prior quarter.
  • Across five years, Goodwill & Intangibles topped out at $28.9 million in Q1 2024 and bottomed at $13.9 million in Q4 2023.
  • Average Goodwill & Intangibles over 4 years is $22.0 million, with a median of $25.3 million recorded in 2025.
  • Peak YoY movement for Goodwill & Intangibles: soared 96.6% in 2024, then dropped 8.68% in 2025.
  • A 4-year view of Goodwill & Intangibles shows it stood at $15.0 million in 2022, then dropped by 7.48% to $13.9 million in 2023, then soared by 95.27% to $27.1 million in 2024, then decreased by 8.68% to $24.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Goodwill & Intangibles were $24.7 million in Q4 2025, $25.3 million in Q3 2025, and $25.9 million in Q2 2025.